Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
Status:
Terminated
Trial end date:
2018-05-10
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well regorafenib and gemcitabine hydrochloride work as
second-line therapy (treatment given when initial treatment doesn't work) in treating
patients with pancreatic cancer that has spread to other parts of the body. Regorafenib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs
used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving regorafenib together with gemcitabine hydrochloride may
kill more tumor cells.